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 CURRENTOPINION Diagnosis of viral hepatitis
Philippa J. Easterbrooka, Teri Robertsb, Anita Sandsc, and Rosanna Peelingd
Purpose of review
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and HIV–HBV and HCV coinfection
are major causes of chronic liver disease worldwide. Testing and diagnosis is the gateway for access to
both treatment and prevention services, but there remains a large burden of undiagnosed infection
globally. We review the global epidemiology, key challenges in the current hepatitis testing response, new
tools to support the hepatitis global response (2016–2020 Global Hepatitis Health Sector strategy, and
2017 WHO guidelines on hepatitis testing) and future directions and innovations in hepatitis diagnostics.
Recent findings
Key challenges in the current hepatitis testing response include lack of quality-assured serological and low-cost
virological in-vitro diagnostics, limited facilities for testing, inadequate data to guide country-specific hepatitis
testing approaches, stigmatization of those with or at risk of viral hepatitis and lack of guidelines on hepatitis
testing for resource-limited settings. The new Global Hepatitis Health Sector strategy sets out goals for
elimination of viral hepatitis as a public health threat by 2030 and gives outcome targets for reductions in
new infections and mortality, as well as service delivery targets that include testing, diagnosis and treatment.
The 2017 WHO hepatitis testing guidelines for adults, adolescents and children in low-income and middle-
income countries outline the public health approach to strengthen and expand current testing practices for
viral hepatitis and addresses who to test (testing approaches), which serological and virological assays to use
(testing strategies) as well as interventions to promote linkage to prevention and care.
Summary
Future directions and innovations in hepatitis testing include strategies to improve access such as through
use of existing facility and community-based testing opportunities for hepatitis testing, near-patient or point-
of-care assays for virological markers (nucleic acid testing and HCV core antigen), dried blood spot
specimens used with different serological and nucleic acid test assays, multiplex and multi-disease platforms
to enable testing for multiple analytes/pathogens and potential self-testing for viral hepatitis.
Keywords
dried blood spot, Global Hepatitis Health Sector strategy, hepatitis B virus, hepatitis C virus, nucleic acid
amplification test, rapid diagnostic test, WHO testing guidelines
INTRODUCTION
Epidemiology and burden
HIV, hepatitis B (HBV) and hepatitis C virus (HCV)
infections are major global public health problems,
with overlapping modes of transmission and
affected populations. It is estimated that 36.9
million people are living with HIV [1,2], 248 million
with chronic HBV (CHB) infection [defined as per-
sistence of hepatitis B surface antigen (HBsAg) for
6 months or more] [3
&&
] and 110 million persons are
HCV antibody-positive, of which 80 million have
viraemic HCV infection [4]. However, the estimates
commonly cited in the published literature vary
widely [5]. Hepatitis B virus and HCV infections
are associated with significant morbidity and
mortality due to chronic liver disease. They account
for approximately 57% of cirrhosis and 78% of
hepatocellular carcinoma (HCC) cases worldwide,
and together they cause an estimated 1.4 million
deaths annually [6]. The burden of HBV and HCV is
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disproportionately high in low-income and
middle-income countries (LMICs), particularly
in Asia and Africa. Worldwide, the majority of
persons with CHB were infected at birth or in early
childhood, and perinatal or horizontal trans-
mission predominates in sub-Saharan Africa (SSA)
and Asia. In contrast, in high-income settings,
such as North America and Europe, transmission
is predominantly via injection drug use and high-
risk sexual behaviours, especially in MSM [7]. In
middle-income and high-income countries, most
HCV infections occur among persons who inject
drugs (PWID), whereas in low-income settings,
HCV infection is most commonly associated
with unsafe injection practices and procedures in
healthcare facilities with inadequate infection
control [8].
HIV–hepatitis B virus and hepatitis C virus
coinfection
As HIV-infected persons continue to live longer
due to increased uptake of antiretroviral therapy
(ART), liver disease has emerged as a leading
cause of morbidity and mortality in HIV-infected
persons coinfected with HBV or HCV [9–14]. Two
recent complementary systematic reviews and
meta-analyses have provided updated regional
estimates of HIV–HBV and HIV–HCV coinfection
across five different population groups [15
&&
,16
&&
].
There is an estimated global hepatitis B surfance
antigen (HBsAg) prevalence of 74% [interquartile
range (IQR) 5.0–11.2%] in HIV-infected persons,
and a burden of 2.73 million (IQR 1.7–4.3 million;
IQR1.3–4.4million)HIV–HBsAgcoinfectedpersons,
based on a systematic review [15
&&
]. The greatest
burden is in SSA (71% of all cases; 1.96 million), as
it is the most affected region for HIV infection (65%
or 22million of total global HIV infections), followed
by Southeast Asia (10% of all cases; 288816). There is
an estimated global HCV antibody (anti-HCV) sero-
prevalence of 6.2% [IQR 3.4–11.9 (IQR 5.0–11.2%)]
inHIV-infectedpersons, and a burdenof 2.28million
(IQR1.3–4.4million)HIV–HCVantibody coinfected
persons [16
&&
], of which 1.36 million are in PWID.
However, in contrast to HIV–HBV infection, the
greatest HIV–HCV burden is in Eastern Europe and
Central Asia (27% of all cases), because of the large
HIV-infected population of PWID, followed by SSA
(19% of all cases). These recent global estimates
of HIV–HBV and HCV coinfection are lower than
the previously reported prevalence of coinfection
[5,9,17–20].
Differences between epidemiology of HIV–
hepatitis B virus and HIV–hepatitis C virus
coinfection
The two companion reviews [15
&&
,16
&&
] highlight
further important distinctions between the epi-
demiology of HIV–HBV and HIV–HCV coinfection.
Prevalence of HCV coinfection varies widely and is
highest in PWID [82.4% (95% confidence interval
(CI) 55.2–88.5)], followed by MSM 6.4% (3.2–10.0),
with much lower rates within the general popu-
lation [2.4% (IQR 0.8–5.8)]. In contrast, HBsAg
prevalence is similar across different HIV-infected
population/exposure groups, and in particular
between the general population (6.6%) and higher
risk behaviour groups such as PWID (7.0%) and
MSM (6.1%). This overall lower HBsAg prevalence,
even in very high-risk groups, is largely because the
majority of HBV infection is acquired perinatally or
in early childhood, many years before HIV acqui-
sition, in contrast to HCV, which is acquired gener-
ally in adulthood, as for HIV. Globally, PWID
accounted for only 7% of all HIV–HBV but 59%
of HIV–HCV coinfections.
Impact of HIV coinfection on natural
history of hepatitis B virus and hepatitis C
virus
The interaction with HIV affects the transmission
and natural history of HBV and HCV infections
[9,10,12,18]. HBV coinfection in HIV-infected
KEY POINTS
 There are an estimated 2.73 and 2.28 million persons
with HIV–hepatitis B surface antigen and HIV–anti-HCV
coinfection globally. The greatest burden of HIV–HBV
coinfection is in sub-Saharan Africa (71% of all cases),
and for HIV–HCV is in Eastern Europe and central Asia
(27% of all cases). The majority of HIV-HCV coinfection
(59% of cases) are in persons who inject drugs.
 The majority of HBV infections are acquired perinatally
or in early childhood, many years before HIV
acquisition, in contrast to HCV, which is acquired
generally in adulthood.
 The current low rate of viral hepatitis testing is a major
barrier to scale-up of access to prevention, care
and treatment.
 Current viral hepatitis testing strategies include initial
serological testing with assays in either rapid
diagnostic test or laboratory-based immunoassay format
followed by virological testing for HBV DNA and HCV
RNA to guide treatment decisions.
 Future directions and innovations in testing include
simplified diagnostic algorithms, point-of-care virological
assays, multi-disease platforms and self-testing for
anti-HCV.
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persons is associated with less spontaneous
clearance of HBsAg, higher rates of chronicity
and occult HBV (HBV DNA detected in the absence
of HBsAg), accelerated fibrosis progression with
increased risk of cirrhosis and HCC and higher
liver-related mortality [9,10,14,18]. HIV infection
also doubles the risk of HCV perinatal trans-
mission in HIV-infected mothers [21,22] and is
associated with less-spontaneous HCV clearance,
higher HCV viral loads and more rapid HCV
disease progression [8,23–25]. Although ART
improves outcomes in both and HCV coinfected
patients, they may also increase the risk of hepa-
toxicity from ART three-fold to five-fold [8,10], and
cross-resistance between HIV and HBV drugs is
common [26].
Strategies for control
Hepatitis B virus
Universal infant and birth-dose hepatitis B vaccina-
tion remains the key strategy for prevention and
control of the HBV epidemic [27]. High levels of
coverage have resulted in a substantial decrease in
new cases of HBV infection in those aged under
15 years [28]. However, rates of adult vaccination
in vulnerable high-risk groups, such PWID, MSM,
sex workers or prisoners, remain low, and these need
to be specifically targeted for hepatitis B and C
testing, catch up hepatitis B vaccination and other
preventive interventions [29]. As Tenofovir (TDF) is
the most effective drug for long-term treatment of
HBV [30], the impressive global scale-up of HIV
testing and treatment [1] together with the increas-
ing adoption of a TDF-based regimen as the pre-
ferred first-line ART in adults and children aged
more than 3 years [31] represents a major global
opportunity to identify and effectively treat those
who also have HBV coinfection, as well as to reduce
mother-to-child transmission.
Hepatitis C virus
The new era of highly curative short-course direct-
acting oral antiviral therapies for HCV has revolu-
tionized the treatment of chronic HCV infection
and offers the potential to not only improve indi-
vidual clinical outcomes but also reduce trans-
mission [32]. There is a need to continue to scale-
up HIV andHCV prevention interventions in higher
risk populations, especially PWID with needle or
syringe exchange programmes, opiate substitution
therapy and provision of ART. This is in addition to
strategies to improve injection safety both world-
wide and especially in Eastern Europe and Southeast
Asia.
GOALS OF HEPATITIS TESTING
Testing and diagnosis of CHB and HCV infection is
the entry point for access to both prevention as well
as care and treatment services. Early identification of
persons with CHB or HCV infection enables them to
receive the necessary care and treatment to prevent
or delay progression of liver disease. Knowledge of
HBV status is important to guide optimal selection
of ART regimens that include use of TDF, but also in
maintaining an agent active against HBV when a
treatment switch is required as withdrawal can be
associated with liver flares and acute on chronic
liver disease [33]. Testing also provides an oppor-
tunity to link to interventions that reduce trans-
mission, such as counselling on risk behaviours
and the provision of prevention commodities
(such as sterile needles and syringes) and hepatitis
B vaccination.
CHALLENGES IN HEPATITIS TESTING
Despite the significant burden of disease due to HBV
and HCV infections and HIV–HBV and HCV coin-
fection, and the advances and opportunities for
treatment, the majority of people coinfected with
HBV or HCV remain undiagnosed and unaware of
their infection [34]. It is estimated that less than 5%
of people with CHB or HCV infection know their
status [34,35
&&
], but in low-income and middle-
income settings, this is even lower (<1%). This is
also particularly poor in populations such as PWID,
prisoners, sex workers andMSM, for whom access to
care and treatment are already challenging [32].
There are several key reasons for this low rate of
hepatitis testing [36]. These include lack of aware-
ness about hepatitis B and C disease and potential
treatments among patients and healthcare workers;
limited facilities or services for hepatitis testing,
including those that can reach most affected and
vulnerable populations, such as harm reduction
services; limited access to reliable and low-cost
HBV and HCV diagnostics, including rapid diagnos-
tic tests (RDTs) and virological assays that are quality
assured by stringent regulatory authorities and/or
WHO prequalified; poor laboratory capacity and
limited access to additional tests to stage liver dis-
ease and guide treatment decisions, such as transi-
ent elastography (e.g. FibroScan); weak hepatitis
surveillance programmes and limited national and
subnational data on epidemiological situation to
guide country-specific hepatitis testing approaches;
high levels of stigma, discrimination and social
marginalization of those with or at risk of viral
hepatitis, such as PWID, MSM, prisoners and sex
workers; lack of testing guidance for low-income
and middle-income settings and a limited evidence
Special commentary
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base to guide hepatitis testing approaches; lack of
political and financial commitment, including from
traditional donors, and that few countries have
designated hepatitis units and budgets within their
health ministries to lead the development of a
hepatitis strategy.
Testing strategies
Hepatitis B virus testing
CHB infection is diagnosed by detection of HBsAg
using serological assays [in either RDT or laboratory-
based immunoassay formats that include the
enzyme immunoassay (EIA), chemiluminescence
immunoassay (CLIA) and electrochemilumines-
cence assay (ECL)] [37
&&
]. Confirmation of the pres-
ence of HBsAg may be carried out by performing a
neutralization step using a specific anti-HBs-con-
taining reagent in the same assay or by repeating
HBsAg testing using a different assay of similar
sensitivity (i.e. two-assay serological testing
strategy). The choice of which format of serological
assays to use will depend on a variety of factors –
most importantly, ease of use and the characteristics
of the testing site, such as storage facilities, infra-
structure, level of staff skills and cost. This is fol-
lowed by measurement of HBV DNA levels and liver
function which, together with staging of liver dis-
ease (based on clinical assessment or use of non-
invasive tests for presence of cirrhosis and of liver
function), guides treatment decisions [30]. HBeAg
may also be useful to assess for viraemic HBV infec-
tion, especially where HBV DNA testing is unavail-
able and where use of TDF prophylaxis to prevent
mother-to-child transmission in mothers with high
levels of viraemia may be indicated. However, there
is a paucity of good quality HBsAg and HBeAg RDTs
on the market, and to date none have met the
requirements for WHO prequalification [38
&
]. In
addition, further studies are needed to validate
the accuracy of HBeAg as a measure of viraemic
infection compared with HBV DNA, given the lack
of correlation in some studies [39].
Hepatitis C virus testing
The principal assays used to determine exposure to
HCV, (indicative of either past or current infection),
rely on detection of antibodies to HCV using rela-
tively inexpensive serological assays. Currently, two
RDTs have been WHO prequalified [38
&
]. However,
such antibody-based assays are unable to detect
infection soon after acquiring HCV infection, as
antibodies may not be detected for 2–3 months in
an individual who has been recently infected. This
diagnostic windowperiod can be shortened by using
assays that also directly detect HCV antigen. Once
exposure to HCV is established, testing for viraemic
HCV infection is performed through detection of
HCV RNA [using either quantitative or qualitative
nucleic acid tests (NAT)] or HCV (p22) core antigen
(HCVcAg).
With HIV coinfection
There are several issues specific to diagnosis of
hepatitis B and C in the context of HIV coinfection.
Studies show a reduced diagnostic performance and
sensitivity of HBsAg assays in HIV-infected persons
[40] but that EIAs perform well. In individuals with
known HIV-positive status, the pooled clinical
sensitivity of RDTs was 72.3% (95% CI: 67.9–
76.4), but specificity was 99.8% (95% CI: 99.5–
99.9), compared with a pooled clinical sensitivity
and specificity of 92.6% (95% CI: 89.8, 94.8) and
99.6% (95% CI: 99, 99.9), respectively, among HIV-
negative persons. Possible explanations for this
reduced sensitivity among HIV-infected persons
include an increased incidence of occult hepatitis
B in HIV-positive persons or the use of TDF or
lamivudine-based antiretroviral regimens, which
are active also against HBV. Generally, the perform-
ance of anti-HCV RDTs is high [41], but there have
been high rates of false positives and false negatives,
particularly using earlier generation HCV serology
assays in surveys in SSA [42]. HCV serological assay
performance, especially RDTs, has not been well
studied in HIV coinfection [41]. There is a need
for further evaluation of the impact of HIV positivity
(and also of CD4þ cell count, viral load and ART
exposure, by regimen) on the sensitivity and speci-
ficity of all serological assays (especially RDTs) for
the detection of HBsAg and anti-HCV, and to further
validate EIAs and RDTs using less invasive and sim-
plermethods of sample collection, such as oral fluid,
capillary whole blood and dried blood spot (DBS)
specimens. Finally, high-quality RDTs for screening
of blood and blood products for transfusion, particu-
larly in emergencies and in low-income settings, are
needed, as current RDTs may not be sufficiently
sensitive to be used for blood screening.
GLOBAL TOOLS TO SUPPORT THE
HEPATITIS RESPONSE
New tools to support the hepatitis global response
include a 2016–2020GlobalHepatitisHealth Sector
(GHHS) strategy with targets for testing and diag-
nosis [35
&&
], andWHO 2017 hepatitis testing guide-
lines for adults, adolescents and children in LMICs
[37
&&
].
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Global hepatitis health sector strategy and
targets
In response to the two World Health Assembly
resolutions on viral hepatitis in 2010 and 2014
[43,44], together with a growing recognition of
the huge public health burden of hepatitis and
opportunities for action, a GHHS strategy on viral
hepatitis was developed and launched in 2016 [34].
This new strategy sets out goals for elimination of
viral hepatitis as a public health threat by 2030 and
outlines a series of impact and service delivery cover-
age targets as well as priority actions to be taken by
countries and the WHO to achieve these targets. A
major service delivery goal is the scale-up of diag-
nosis and those on treatment. For HBV infection,
this means at least 30% diagnosed by 2020 and 90%
by 2030 (compared with <1% in 2015) and a cor-
responding 8 million persons receiving hepatitis
treatment by 2020 (5 million HBV and 3 million
HCV) and 80% of those eligible by 2030 (compared
with 2015 baseline of <1%).
Recommendations of WHO 2017 testing
guidelines
These are the first global guidelines on testing for
CHB and HCV infections directed at LMICs [37
&&
]
and complement published guidance by WHO on
the prevention, care and treatment of CHB [30] and
HCV [32] infections. The guidelines outline the
public health approach to strengthening and
expanding current testing practices for viral
hepatitis and address what serological and virolog-
ical assays to use (testing strategies), and who to test
(testing approaches), as well as interventions to
promote linkage to prevention and care. They are
intended for use across different age groups and
populations. The target audiences are national pro-
gramme managers in ministries of health and
healthcare providers in LMICs responsible for plan-
ning and implementing hepatitis testing, preven-
tion, care and treatment services. The Grading of
Recommendations, Assessment, Development and
Evaluation system was used to categorize both the
strength of recommendations as strong or con-
ditional (based on consideration of the quality of
evidence, balance of benefits and harms, acceptabil-
ity, resource use and programmatic feasibility) and
the quality of evidence as high, moderate, low or
very low.
These guidelines also build on a decade of evol-
ution in WHO HIV testing guidance [45] that
includes provider-initiated testing guidance, service
delivery guidance, couples testing and home based
testing and recent guidance on self-testing. The key
recommendations on who to test and testing
approaches, how to test and testing strategies, and
interventions to promote uptake of testing and link-
age to care are summarized below, and the algor-
ithms for diagnosis, management and monitoring
are presented in Figs 1 and 2.
Who to test for hepatitis B virus and
hepatitis C virus infection: testing
approaches
The guidelines recommend to offer focused testing
to individuals from populations most affected by
HBV or HCV infection (i.e. who are either part of a
population with higher seroprevalence or who have
a history of exposure or high-risk behaviours for
HBV or HCV infection), such as PWID, prisoners,
MSM and persons infected with HIV. In settings
with a seroprevalence of at least 2 to 5% of HBsAg
or HCV antibody (anti-HCV), it is recommended
that all adults have routine access and be offered
testing (i.e. a general population testing approach)
or to use ‘birth cohort’ testing for specific age groups
with higher anti-HCV seroprevalence. These differ-
ent testing approaches should make use of existing
facility-based [such as antenatal clinics (ANC), HIV
or TB services] or community-based testing oppor-
tunities including HIV testing programmes, but
highlight that targeted approaches may be required
for PWID and MSM in whom stigmatization and
other factors may limit access to services for testing
and treatment.
How to test for hepatitis B virus and
hepatitis C virus infections: serological
assays and testing strategies
Overall, the guidelines recommend the use of a
single quality-assured serological assay (i.e. either
a laboratory-based EIA or RDT to detect HBsAg and
anti-HCV). Assays used should meet minimum
performance standards and preferably be delivered
at the point-of-care to improve access and linkage to
care and treatment.
Confirming viraemic infection and
monitoring for treatment response
Following reactive anti-HCV serology, a quantitat-
ive or qualitative RNA NAT is recommended as the
preferred testing strategy to diagnose viraemic infec-
tion. Detection of core HCV antigen, in which the
assay has comparable clinical sensitivity with NAT
technologies, may be considered as an alternative.
The use of HBV DNA NAT following reactive HBsAg
serology is recommended to help further guide who
to treat or not treat if there is no evidence of cirrhosis
and to monitor for treatment response based on
existing recommendations from the 2015 WHO
HBV management guidelines [30].
Special commentary
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Use of dried blood spot specimens and
other strategies to promote uptake of
testing and linkage to care
The use of capillary (finger-stick or heel-stick) whole
blood DBS specimen collection for both serological
and NAT assays for HBV and HCV infection may be
considered in order to facilitate access to testing:- in
certain settings where there are either no facilities or
expertise to take venous blood specimens; in persons
with poor venous access; or where quality assured
RDTs are not available or their use is not feasible.
Programmes should consider only the use of assays
that have been validated by their manufacturer for
use with DBS specimens. Other recommended inter-
ventions to promote uptake of hepatitis testing and
linkage to care include peer and lay health worker
support in community-based settings, clinician
reminders to offer testing in facilities, and testing
as part of integrated services within drug treatment
and community-based harm reduction services.
FIGURE 1. Summary algorithm for diagnosis, management and monitoring of chronic hepatitis B infection (Reproduced from
[35&&]).
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IMPLEMENTATION CONSIDERATIONS
AND FUTURE DIRECTIONS
Guidance on implementation
These guidelines also provide practical guidance on
different service delivery models for testing, pre-test
and post-test counselling and tailored testing
approaches in specific populations (e.g. PWID, pris-
oners, pregnant women, couples and partners,
children and adolescents). To support national
implementation of these recommendations in
LMICs, there is also a framework for country
decision-making and planning in several key areas
as summarized in Fig. 3 [37
&&
].
Country requirements for implementation
Important future directions in hepatitis testing will
include the following:
FIGURE 2. Summary algorithm for diagnosis, management and monitoring of chronic hepatitis C infection (Reproduced from
[35&&]).
Special commentary
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Service delivery models: Service delivery of
hepatitis testing may be optimized by integrating
hepatitis testing into other healthcare and testing
services such as HIV and sexually transmitted infec-
tion clinics, antenatal services, drug dependency
and prison services to increase efficiency, reach
and acceptability. There is also a need to expand
opportunities for community-based testing to reach
marginalized groups and ensure equitable access to
testing. Appropriate models of integration and link-
age will depend on the country context and health
system.
Adaptation of the WHO hepatitis testing guidance
into national hepatitis plans and policies according to
country epidemiological context and health sys-
tems that target priority populations and locations.
For example, priority might be given to specific age
groups (such as those born between certain dates),
certain high prevalence groups (such as incarcerated
persons, people who inject drugs, migrants, haemo-
dialysis patients, people who undergo skin-piercing
procedures including tattooing, some indigenous
communities, sex workers andMSM) and those with
evidence of liver disease.
The 3As- Accuracy, Access and Affordability
represent key considerations in implementing test-
ing services. Figure 4 illustrates the type of assays
that can be deployed at different levels of the
national healthcare system taking into consider-
ation the capacity of facilities, human resources/
technical expertise and infrastructure/environmen-
tal demands (e.g. electrical, refrigeration and may
involve a trade-off between accuracy and access to
achieve greater coverage of testing. For example, at
the community or primary healthcare level, testing
must be simple and able to be performed by a
community worker with use of RDTs. Countries also
need to assess the costs of implementing a testing
programme and determine what are the drivers of
costs to maximize resources. There is a need for
simple easy-to-use tools for costing and modelling
to support country business plan developments.
Strengthening of national laboratory systems to
provide quality diagnosis of CHB and HCV infec-
tion, and a reliable supply of quality-assured (WHO-
prequalified) diagnostics, with simplification of the
hepatitis diagnostic pathway. There is a need for
more reliable and low-cost RDTs for viral hepatitis B
and C, point-of-care (POC) testing for monitoring
hepatitis B and C viral load (and hepatitis C antigen)
to guide treatment decisions and simplified tests for
assessing liver fibrosis and cirrhosis.
Accurate forecasting of country and global needs in
diagnostic commodities. Effective testing programmes
rely on an uninterrupted supply of diagnostics.
Robust procurement and supply management
FIGURE 3. Implementation considerations for national hepatitis programmes. (Reproduced from [35&&]).
Diagnosis of viral hepatitis Easterbrook et al.
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systems, such as bulk procurement with staggered
deliveries, advanced purchasing and improved
forecasting are required to ensure savings on pro-
curement and introduce efficiencies in supply man-
agement.
Quality assurance of hepatitis diagnostics
and the WHO prequalification programme
A key barrier to the more widespread adoption of
testing is the current lack of quality-assured RDTs.
An important contributor to facilitating access to in-
vitro diagnostics (IVDs) of good quality and building
the capacity of national authorities to more effec-
tively monitor quality of IVDs is the WHO Prequa-
lification of Diagnostics programme that includes
hepatitis B and C diagnostics [38
&
,46]. Only a third
of countries have some type of regulatory system in
place for IVDs; and even where regulations for IVDs
exist, often they are not enforced. WHO specifically
targets prequalification of the type of IVDs more
commonly used in resource-limited settings such as
RDTs and EIAs without automated test procedures,
which are generally not used in high-income
countries where sophisticated centralized labora-
tory infrastructure exist.
The current WHO prequalification pipeline for
hepatitis diagnostic assays as of December 2016
includes eight HCV IVDs and two HBsAg IVDs that
are considered eligible to proceed for WHO prequa-
lification according to standardized procedures. To
date, two anti-HCV RDTs, two anti-HCV EIAs, one
anti-HCV line immunoassy, four HBsAg EIAs have
been WHO prequalified. RDTs with a high degree of
easeofuse thatcanbeusedwithcapillary (fingerstick)
wholebloodwith reduced requirement for cold chain
storage will be prioritized given their unique appli-
cability in resource-limited settings where infrastruc-
ture and human resources are lacking.
DIAGNOSTIC INNOVATIONS AND FUTURE
DEVELOPMENTS
Advances in hepatitis virus detection technology
have also created new opportunities for enhancing
hepatitis testing, as well as monitoring of response
to treatment [42]. Future directions and innovations
in testing include simplified single virological assay
testing strategies, assays for near-patient or POC use
for NAT and core antigen, DBS,multiplex andmulti-
disease platforms and self-testing for anti-HCV.
Simplified testing strategies
Simplifying testing algorithms will be critical to
ensuring affordability and the success of scaling
FIGURE 4. Matching diagnostic needs and capacity at different levels of the national healthcare system, with provision of
different types of tests depending on the type of facility. Serology: CLIA, chemiluminescence immunoassay; ECL,
electrochemiluminescence immunoassay; EIA, enzyme immunoassay; IA, laboratory-based immunoassay; RDT, rapid
diagnostic test.; Virology: HCVcAg, HCV core antigen; Lab-NAT; laboratory-based NAT; NAT, nucleic acid test; POC-NAT,
point-of-care NAT (Reproduced from [35&&]).
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up testing. Potential future testing approaches
for HCV infection are the adoption of a less-
expensive and more manageable single virological
tests for both diagnosis and confirmation of virae-
mia [47,48]. However, this may only ever be cost-
effective in high-prevalence settings and high-risk
populations.
Near-patient or point-of-care testing
The development of reliable, accurate, practical
and affordable assays that may be used at or near
to POC will be crucial for expanding hepatitis
testing services, especially in community-based
settings, where there are challengeswith cost, trans-
port and venepuncture requirements [49]. These
technologies for viral hepatitis include molecular
NAT-based tests for diagnosis and treatment
monitoring and HCVcAg testing. These emerging
POC devices are able to perform conventional
laboratory molecular testing (qualitative and quan-
titative) in field settings; are easier to use than
the laboratory-based NAT assays, as they require
minimum training; can be operated on battery
or conventional power source; do not require
phlebotomy and provide a result within 2h.
Among these are cartridge-based HCV RNA assays,
which can be used with existing diagnostic
platforms developed for tuberculosis or HIV early
infant diagnosis and viral load monitoring. There
are also HCVcAg POC platforms in development.
These devices offer the possibility of a same-day
diagnosis of viraemic infection, either alone or
when combined with an HCV antibody RDT, and
for test of cure. Outstanding research questions
include establishing the distribution of HCV viral
load at diagnosis and in the context of viral rebound
with treatment failure [and, specifically, the pro-
portion of patients with low viral loads missed by
assays that have higher limits of detection (e.g.
3000 IU/ml)]. This information will be useful in
assessing the clinical utility of HCV qualitative
versus quantitative RNA assays and optimizing
the development of future HCV RDTs for HCVcAg
detection, including as a one-step diagnostic strategy
in a range of higher prevalence settings. A quantitat-
ive HBsAg test is currently under evaluation as a
potentially simplifiedalternative strategy toascertain
high levelsof viraemia, rather thana test forHBeAgor
HBV DNA [50].
Dried blood spot specimens
Validation of existing assays that can be used with
DBS for serological diagnosis, as well as detection
and quantification of HCV RNA and HBV DNA,
show promise for extending access to hepatitis
testing especially in community-based settings.
Two recent reviews showed good diagnostic
performance using DBS sampling with different
commercial hepatitis serological and NAT assays
[51,52]. DBS has been used extensively for early
infant diagnosis of HIV but the quality of DBS
specimens varies widely due to different collec-
tion, drying and storage and elution methods.
However, one major challenge in programmes
using DBS is linkage to care. Although DBS can
be collected at remote sites, specimens have to be
sent off to centralized laboratories for testing,
often creating major delays in result reporting.
Priority areas for research and development
include DBS specimen validation by manufac-
turers of commercial serological and NAT assays,
and application for stringent regulatory approval
and WHO prequalification to use DBS as an
additional specimen type.
Multiplex and multi-disease analysers
Multiplex and multi-disease analysers allow for
integrated testing of hepatitis B and C alongside
other pathogens, for example HIV and syphilis,
and can leverage technology developed for other
infectious disease programmes. Key advantages
include the requirement for lower specimen
volume, improved client flow with results for
multiple pathogens available at the same time and
so fewer patient visits and transport costs. Multi-
plex RDTs are in development for anti-HIV/anti-
HCV, anti-HIV/syphilis/anti-HCV, anti-HIV/syphi-
lis/HBsAg and anti-HIV/anti-HCV/HBsAg. Data on
their diagnostic accuracy and impact on patient-
important outcomes are required before adoption.
Typically, they are most suitable for district, provin-
cial and national laboratories as the current analysers
may require certain precision steps, utilize serum/
plasma specimens and require constant electricity
supply and regular maintenance.
Self-testing
Self-testing is a process in which an individual, who
wants to know his or her status, collects a specimen,
performs a test and interprets the result themselves,
often in private. HIV self-testing is now being con-
ducted inmany settings and has increased uptake of
testing among people not reached by other existing
HIV testing services, many of whom are first-time
testers [53]. The experience with hepatitis self-test-
ing is currently very limited, but it represents a
potentially important approach to expand access
to testing in the future.
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Service delivery
In addition to these technological innovations,
there have been advances in the mode of delivery
of testing, so that promising new technologies reach
target populations. Supply chain management is
one of the major challenges in healthcare delivery
in low-income rural settings where there is limited
access to laboratories or any form of diagnostic
testing. Although assays for use at POC can help
increase access to hepatitis testing, such decentral-
ization of testing can also place major stresses on
already fragile health systems. Unmanned aerial
vehicles (UAVs), also referred to as drones, are
remotely operated robotic airplanes that have
emerged as a potentially valuable technology to
deliver healthcare supplies, such as RDTs, DBS
specimens, blood products and vaccines, to remote
locations with poor transport routes, especially
during the rainy season [53]. UAVs can carry a
payload of 2–3kg (sufficient for 100 RDTs), fly a
distance of approximately 60km and either land
or do aerial drops of their payload onto a target
area. Pilot projects in HIV and other areas are
ongoing in Malawi, Rwanda, Zambia, the Domini-
can Republic, Haiti, Papua New Guinea and Bhutan
[54–57].
A further priority is to address key research gaps
that will in turn inform future global guidance on
viral hepatitis testing in LMICs. In particular, there
is a need for formal evaluation of different HBV and
HCV testing approaches [i.e. routine general popu-
lation, focused risk-based, antenatal clinic (ANC)
and birth cohort testing] using different service
delivery models (community-facility-based or
health-facility-based). This can take the form of
comparative trials, large-scale implementation stud-
ies or demonstration projects in a range of epidemic
settings and populations in LMICs.
CONCLUSION
To overcome current challenges in hepatitis testing
and substantially increase awareness of hepatitis
status and earlier diagnosis, there is a need to pro-
vide a secure supply of quality-assured affordable
diagnostics, services that can reach those popu-
lations most affected, well functioning laboratories
to ensure high-quality testing and treatment
monitoring, an appropriately trained health work-
force and active involvement of affected commun-
ities. The new WHO global testing guidelines
provide a major opportunity to improve identifi-
cation and treatment of persons with CHB and HCV
infection, and achieve the 2016 Global Health
Sector Strategy on viral hepatitis targets on testing
and treatment. This will, in turn, improve clinical
outcomes, save lives and reduce hepatitis B and C
transmission. Advances in hepatitis virus detection
technology have created new opportunities for
enhancing testing referral and treatment, with sim-
plified one-assay testing algorithms, use of POC
molecular tests, multiplex or polyvalent testing,
self-testing and new modes of service delivery.
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